Statistical analysis
Based on the previous phase 3 studies (L-PLUS 1 study, L-PLUS 2 study), the percentage of patients in the lusutrombopag and placebo groups meeting the primary endpoint was estimated at 41.9% and 3.4%, respectively. A sample size of 54 patients: the lusutrombopag group (For efficacy, the population under primary analysis was the FAS (full analysis set) or all patients who were randomized based on the intention-to-treat principle, while the safety analysis entailed the use of the safety set (SS) that was all randomized patients receiving a minimum of one study drug.SAS (V 9.4, SAS Institute, USA) was employed for all analyses with significance at a 